Matthew Maenner is surveillance team lead for the National Center on Birth Defects and Developmental Disabilities at the U.S. Centers for Disease Control and Prevention.
Matthew Maenner
Surveillance team lead
National Center on Birth Defects and Developmental Disabilities
From this contributor
Q&A with Matthew Maenner: Estimating autism prevalence quickly
A new method to track autism prevalence in 11 U.S. states is twice as fast as the old approach — and yields similar results.
Q&A with Matthew Maenner: Estimating autism prevalence quickly
By
Peter Hess
13 July 2021 | 6 min read
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
By
Ashley Juavinett
30 March 2026 | 8 min read
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
By
Dalmeet Singh Chawla
27 March 2026 | 5 min read
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
By
Claudia López Lloreda
26 March 2026 | 4 min read